Zachary Scott Wallace
Amgen Inc.
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Vasculitis and related conditions
Strong evidence · 6 supporting papers · latest 2026
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Strong evidence · 2 supporting papers · latest 2026
IgG4-Related and Inflammatory Diseases
Strong evidence · 2 supporting papers · latest 2026
SARS-CoV-2 and COVID-19 Research
Strong evidence · 3 supporting papers · latest 2026
Respiratory viral infections research
Strong evidence · 1 supporting paper · latest 2025
Rheumatoid Arthritis Research and Therapies
Solid evidence · 5 supporting papers · latest 2026
Systemic Sclerosis and Related Diseases
Solid evidence · 5 supporting papers · latest 2026
COVID-19 Clinical Research Studies
Solid evidence · 3 supporting papers · latest 2026
Publications (15)
Treatment of ANCA-Associated Vasculitis With Avacopan: Results of the ADVOCATE Trial After Readjudication of the Primary Endpoint
2026DOI
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
2026DOIPMID 42128703
Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease
2025DOIPMID 41072235
Real-world clinical and economic burden of immunoglobulin-G4-related disease in the United States: A retrospective claims-based analysis
2026DOIPMID 41861174
Real-World Effectiveness and Safety of Avacopan in ANCA-Associated Vasculitis: A Systematic Literature Review and Meta-analysis
2026DOI
Avacopan for the Treatment of ANCA-Associated Vasculitis: The Primary Endpoints Readjudication
2026DOI
Effectiveness and Safety of Avacopan in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
2026DOI
Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA
2025DOIPMID 41106411
Longitudinal Trajectories of Kidney Function in Patients with Severe ANCA-Associated Vasculitis
2025DOIPMID 41325129
Autoantibodies and Risk for Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease With Comparisons to Idiopathic Pulmonary Fibrosis and Healthy Controls
2026DOI
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial
2025DOIPMID 41289027
B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study
2026DOIPMID 42581601
Differences in SARS ‐ CoV ‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER ‐Adult Cohort Study
2026DOIPMID 42045807
Development and initial validation of a brief measure of uncertainty in rheumatic disease
2026DOIPMID 41618957
A Post-Marketing Evaluation of Avacopan Safety with a Focus on Hepatic Adverse Events
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Amgen Inc.
Source: OpenAlex · retrieved 2026-09-29